Clinical trials: Patients with Multiple Sclerosis
Spasticity, Multiple Sclerosis
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
This is a multicenter, randomized (1:1:1), double-blind, active and placebo controlled, parallel group study to evaluate safety, tolerability and efficacy of oral arbaclofen in MS patients with spasticity.
- Trial name
- NCT01743651
- Testing
- arbaclofen, baclofen
- Where
- 48 sites in United States, Russia and 1 more
- Volunteers
- 353 people
- Sponsor
- RVL Pharmaceuticals, Inc.
Multiple Sclerosis
Transcutaneous Posterior Tibial Nerve Stimulation in Patients With Multiple Sclerosis Related Urge Incontinence
Recently, several studies have investigated the safety and efficacy of the Stoller afferent nerve stimulation (SANS) treatment in Multiple Sclerosis (MS) patients.
- Trial name
- SANS-REHAB (NCT06314412)
- Testing
- Stoller's Afferent Nerve Stimulation (SANS)
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Istituto Auxologico Italiano
Multiple Sclerosis
Rebif Compliance Support Program - Assessing Needs in Multiple Sclerosis
This 1-arm, open-label, multicentric, observational study aims to collect subject centric information in line with routine care.
- Trial name
- AIMS (NCT01080573)
- Where
- United Kingdom
- Volunteers
- 1,257 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Chronic Progressive
Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis
Preliminary not-controlled clinical studies of the efficacy of monthly intravenous cyclophosphamide administration in secondary progressive multiple sclerosis reported encouraging results, but no randomized controlled trial has…
- Trial name
- PROMESS (NCT00241254)
- Testing
- Cyclophosphamide (drug), Methylprednisolone (drug)
- Where
- 26 sites in France
- Volunteers
- 138 people
- Sponsor
- University Hospital, Bordeaux
Multiple Sclerosis
Transcranial Electrical Stimulation in Multiple Sclerosis
First the investigators will examine if the blood flow in the brain is different in patients with Multiple Sclerosis compared to healthy volunteers. HOW? The blood flow of the subjects is imaged by use of a special MRI-technique.
- Trial name
- TEMS (NCT06966128)
- Testing
- transcranial Direct Current Stimulation
- Where
- 2 sites in Belgium
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Relapsing Remitting Multiple Sclerosis (RRMS)
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
This study evaluated disease control during different lengths of treatment transition from natalizumab to fingolimod.
- Trial name
- TOFIINGO (NCT01499667)
- Testing
- Fingolimod
- Where
- 44 sites in Australia, Austria and 9 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis (RRMS)
MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)
This is a Phase 2 multicenter, double-blind, placebo-controlled, randomized, parallel-group trial to assess the efficacy and safety of 2 once-daily oral doses of IMU-838 (vidofludimus calcium), a small molecule inhibitor of…
- Trial name
- EMPhASIS (NCT03846219)
- Testing
- IMU-838 (30 mg/day), IMU-838 (45 mg/day), IMU-838 (10 mg/day)
- Where
- 38 sites in Bulgaria, Poland and 2 more
- Volunteers
- 210 people
- Sponsor
- Immunic AG
Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases
This is an open label, single-site, dose-escalation study in up to 15 participants with relapsed or refractory Neurological Autoimmune Diseases.
- Conditions
- Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis, Myasthenia Gravis
- Trial name
- NCT07392528
- Testing
- QT-019C
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Tianjin Huanhu Hospital
Multiple Sclerosis
Benefits Evaluation of Selfia® Adapted Underwear for MS Patients Performing Self-catheterization
KML is a multicenter, prospective, uncontrolled and before/after study. The study aims to estimate if the use of Selfia ® adapted underwear reduces the necessary duration for the realization of self-catheterisation (SC) for…
- Trial name
- KML (NCT02889419)
- Testing
- Evaluation of underwear Selfia®
- Where
- 6 sites in France
- Sponsor
- Lille Catholic University
Multiple Sclerosis Acute and Progressive
Assessment of Quality of Life and Psychological Problems in Patients With Multiple Sclerosis
1. use QoL assessments to check whether interventions have been as effective from the patient's point of view as from the clinician's, and to determine whether further action is required .
- Trial name
- NCT05029830
- Testing
- investigations like MRI..
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis
Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis
Fibroblasts have demonstrated potent immune modulatory and therapeutic activity in the experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis, as well as in other models of autoimmune and inflammatory…
- Trial name
- MSFibroblast (NCT05080270)
- Testing
- Tolerogenic Fibroblasts
- Where
- Mexico
- Volunteers
- 5 people
- Sponsor
- FibroBiologics
Multiple Sclerosis, Neuromyelitis Optica
Lifestyle Weight Management Program: Interviews and Stakeholder Meetings.
Background: An assessment by paediatric neurologists specializing in demyelinating conditions brought attention to the rapid weight change seen among patients recently diagnosed with, and receiving therapy for, neuromyelitis…
- Trial name
- NCT05070286
- Testing
- Observational Study.
- Where
- United Kingdom
- Volunteers
- 45 people
- Sponsor
- Oxford Brookes University
Multiple Sclerosis
Cardiovascular Fitness of Patients With Multiple Sclerosis, Effect of Exercise on Fatigue and Depression
This study is focused on patients with multiple sclerosis (MS), their cardiovascular fitness, and the effect of combined controlled training on the perception of fatigue, the development of depression, and quality of life in the…
- Trial name
- NCT05671588
- Testing
- Controlled combined exercise group, Conventional rehabilitation
- Where
- Czechia
- Volunteers
- 70 people
- Sponsor
- University Hospital Ostrava
Multiple Sclerosis, Overactive Bladder Syndrome
Effect of TTNS and PNS on Neurogenic Overactive Bladder Symptoms in Female Patients With Multiple Sclerosis.
This study aims to evaluate the use of transcutaneous tibial nerve stimulation (TTNS) and parasacral nerve stimulation (PSS) methods in the treatment of overactive bladder (OAB) symptoms in patients with Multiple Sclerosis (MS)…
- Trial name
- NCT06143397
- Testing
- TTNS (Transcutaneous tibial nerve stimulation), PNS (Parasacral nerve stimulation), Behavioral treatment
- Where
- Turkey (Türkiye)
- Volunteers
- 42 people
- Sponsor
- Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
This phase I/II trial is studying the side effects and best dose of flavopiridol and to see how well it works in treating patients with lymphoma or multiple myeloma.
- Conditions
- Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma
- Trial name
- NCT00112723
- Testing
- alvocidib
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Lymphangioleiomyomatosis, Tuberous Sclerosis Complex
Safety of Simvastatin in LAM and TSC
The purpose of this research study is to see if simvastatin can be taken safely in patients with either LAM or TSC, who are already being treated with everolimus or sirolimus.
- Trial name
- SOS (NCT02061397)
- Testing
- Simvastatin, Sirolimus Oral Product, Everolimus Oral Product
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pennsylvania
Multiple Sclerosis, Relapsing-Remitting
A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
The primary objective of this study is to evaluate the radiological efficacy of SC natalizumab over time through Week 24 in natalizumab-naïve participants, as measured by brain magnetic resonance imaging (MRI).
- Trial name
- NCT05532163
- Testing
- Natalizumab
- Where
- 2 sites in Germany
- Volunteers
- 1 people
- Sponsor
- Biogen
Multiple Sclerosis
Exopulse Mollii Suit, Spasticity & Tissue Oxygenation
Spasticity is a frequent and debilitating symptom in patients with multiple sclerosis (MS). Sustained contractile activity, such as that observed in spastic muscles, could reduce the capillary density and induce important changes…
- Trial name
- ENNOX (NCT05362006)
- Testing
- Exopulse Mollii Suit
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Institut De La Colonne Vertebrale Et Des Neurosciences
Multiple Sclerosis, Walking
Validity and Reliability of the L Test in Single and Dual Task Conditions in Multiple Sclerosis
Motor problems and cognitive deficits affecting walking and balance are frequently observed in individuals with MS. As a result of problems occurring in the motor and sensory systems, walking becomes less automatic and greater…
- Conditions
- Multiple Sclerosis, Walking, Validity During Daily Activities
- Trial name
- NCT07186998
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Sanko University
Multiple Sclerosis (MS) Primary Progressive
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Orelabrutinib is a CNS-penetrable BTK inhibitor. This is a phase 3, randomized, double-blind, parallel-group, multicenter study to evaluate the efficacy and safety of orelabrutinib compared with placebo in patients with PPMS.
- Trial name
- NCT07067463
- Testing
- Orelabrutinib
- Where
- 83 sites in United States, Australia and 15 more
- Volunteers
- 705 people
- Sponsor
- Zenas BioPharma (USA), LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.